ArticleChina CDC weekly2026
Five-Year Immune Recovery After ART Initiation Among PLWH Aged ≥15 Years with Baseline Immunosuppression - China, 2013-2024.
Article in China CDC weekly, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Although antiretroviral therapy (ART) suppresses human immunodeficiency virus (HIV) replication in most people living with HIV (PLWH), 10%-40% show inadequate CD4 reconstitution despite sustained virologic suppression, increasing risks of AIDS- and non-AIDS-related events. Prior studies have suggested that immunological nonresponse (INR) is particularly common among individuals starting ART with immunosuppression. In China, real-world evidence for long-term immune recovery in immunosuppressed PLWH remains limited. Methods: Immunosuppression was defined as a baseline CD4<350 cells/µL at ART initiation. At year 5, INR was defined as CD4<350 cells/µL and favorable immune recovery as CD4 ≥500 cells/µL. From China's National ART Cohort, we included PLWH (aged ≥15 years; baseline CD4 <350 cells/µL) initiating ART during 2013-2019 who achieved year-5 virologic suppression (≤50 copies/mL). We described 5-year CD4 changes and examined factors associated with year-5 immune outcomes. Results: Among 315,109 participants, the median CD4 count increased from 199 cells/µL at baseline to 424 cells/µL over 5 years of ART. At year 5, 111,899 (35.5%) had CD4≥500 cells/µL (favorable immune recovery). In contrast, 109,344 (34.7%) patients had a CD4 <350 cells/µL and were classified as having INR. Lower baseline CD4 counts, older age, male sex, heterosexual or injection drug transmission, HBsAg positivity, anti-HCV positivity, and delayed ART initiation were associated with higher odds of INR. Compared to continuous non-nucleoside reverse transcriptase inhibitor (NNRTI)-based therapy, continuous protease inhibitor (PI)- and integrase strand transfer inhibitor (INSTI)-based therapies, and switching from NNRTI- to INSTI-based regimens showed higher odds of favorable immune recovery. Conclusions: Among PLWH who initiated ART with immunosuppression and achieved virologic suppression at 5 years, most experienced immune recovery; however, approximately one-third remained INR. Early diagnosis, timely ART initiation, and targeted long-term immunological monitoring are required for populations at increased risk of suboptimal immune recovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.